TY - JOUR
T1 - Mapping the literature
T2 - Role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma
AU - Le Cesne, Axel
AU - Domont, J.
AU - Cioffi, A.
AU - Bonvalot, S.
AU - Terrier, P.
AU - Ray-Coquard, I.
AU - Alfaro, V.
AU - Lebedinsky, C.
AU - Santabarbara, P.
AU - Blay, J. Y.
PY - 2009/6/1
Y1 - 2009/6/1
N2 - This bibliographic review evaluated phase II clinical trials aimed at the identification of antitumor activity of single agents in soft tissue sarcoma (STS) after failure of standard-of-care therapy including anthracyclines and ifosfamide. A total of 63 articles (on anthracyclines, ifosfamide, trabectedin and 27 investigational agents) were included (data from 1979 to 2008). Trabectedin is the most extensively studied agent in patients with STS after failure of anthracyclines and ifosfamide (457 patients), followed by ifosfamide (412), cisplatin (144), temozolomide (137), docetaxel (114), gemcitabine (112), etoposide (95) and doxorubicin (59). Dacarbazine and the remaining investigational agents have usually been tested in 50 or fewer patients, with vastly negative results not warranting further investigation. Methodological limitations are identified in the majority of the reviewed phase II studies, including small sample size, single-institution studies, lack of independent review of the antitumor responses and inadequate description of previous therapies/agents. However, all trabectedin studies fulfilled these methodological characteristics relevant for a phase II trial. A phase II randomized trial confirmed the results of 3 prior nonrandomized studies and, therefore, trabectedin is currently considered an important new option to control advanced sarcomas in patients with STS following failure of all conventional treatments.
AB - This bibliographic review evaluated phase II clinical trials aimed at the identification of antitumor activity of single agents in soft tissue sarcoma (STS) after failure of standard-of-care therapy including anthracyclines and ifosfamide. A total of 63 articles (on anthracyclines, ifosfamide, trabectedin and 27 investigational agents) were included (data from 1979 to 2008). Trabectedin is the most extensively studied agent in patients with STS after failure of anthracyclines and ifosfamide (457 patients), followed by ifosfamide (412), cisplatin (144), temozolomide (137), docetaxel (114), gemcitabine (112), etoposide (95) and doxorubicin (59). Dacarbazine and the remaining investigational agents have usually been tested in 50 or fewer patients, with vastly negative results not warranting further investigation. Methodological limitations are identified in the majority of the reviewed phase II studies, including small sample size, single-institution studies, lack of independent review of the antitumor responses and inadequate description of previous therapies/agents. However, all trabectedin studies fulfilled these methodological characteristics relevant for a phase II trial. A phase II randomized trial confirmed the results of 3 prior nonrandomized studies and, therefore, trabectedin is currently considered an important new option to control advanced sarcomas in patients with STS following failure of all conventional treatments.
UR - http://www.scopus.com/inward/record.url?scp=70350068771&partnerID=8YFLogxK
U2 - 10.1358/dot.2009.45.6.1378934
DO - 10.1358/dot.2009.45.6.1378934
M3 - Review article
C2 - 19649331
AN - SCOPUS:70350068771
SN - 1699-3993
VL - 45
SP - 403
EP - 421
JO - Drugs of Today
JF - Drugs of Today
IS - 6
ER -